NASDAQ:HUMA Humacyte (HUMA) Stock Price, News & Analysis $5.72 +0.24 (+4.38%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Humacyte Stock (NASDAQ:HUMA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Humacyte alerts:Sign Up Key Stats Today's Range$5.37▼$5.7850-Day Range$4.86▼$7.0552-Week Range$1.96▼$9.97Volume2.88 million shsAverage Volume2.33 million shsMarket Capitalization$681.16 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingBuy Company OverviewHumacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Humacyte Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks72nd Percentile Overall ScoreHUMA MarketRank™: Humacyte scored higher than 72% of companies evaluated by MarketBeat, and ranked 299th out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingHumacyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageHumacyte has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Humacyte's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Humacyte are expected to grow in the coming year, from ($1.09) to ($0.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Humacyte is -4.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Humacyte is -4.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHumacyte has a P/B Ratio of 44.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Humacyte's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.38% of the float of Humacyte has been sold short.Short Interest Ratio / Days to CoverHumacyte has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Humacyte has recently increased by 14.42%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHumacyte does not currently pay a dividend.Dividend GrowthHumacyte does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted16.38% of the float of Humacyte has been sold short.Short Interest Ratio / Days to CoverHumacyte has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Humacyte has recently increased by 14.42%, indicating that investor sentiment is decreasing significantly. News and Social Media2.9 / 5News Sentiment0.15 News SentimentHumacyte has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Humacyte this week, compared to 4 articles on an average week.Search Interest26 people have searched for HUMA on MarketBeat in the last 30 days. This is an increase of 86% compared to the previous 30 days.MarketBeat Follows23 people have added Humacyte to their MarketBeat watchlist in the last 30 days. This is an increase of 667% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Humacyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,869,996.00 in company stock.Percentage Held by Insiders23.10% of the stock of Humacyte is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.71% of the stock of Humacyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Humacyte's insider trading history. Receive HUMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter. Email Address HUMA Stock News HeadlinesKirby McInerney LLP Announces Investigation of Shareholder Claims Against Humacyte, Inc. (HUMA)October 23 at 6:41 PM | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of InvestorsOctober 23 at 2:18 PM | businesswire.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of InvestorsOctober 22 at 9:03 PM | businesswire.comThe Law Offices of Frank R. Cruz Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of InvestorsOctober 22 at 7:16 PM | businesswire.comHumacyte Is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLPOctober 21 at 1:33 PM | theglobeandmail.comHumacyte (NASDAQ:HUMA) Rating Reiterated by TD CowenOctober 20, 2024 | americanbankingnews.comBTIG Research Reiterates Buy Rating for Humacyte (NASDAQ:HUMA)October 20, 2024 | americanbankingnews.comSee More Headlines HUMA Stock Analysis - Frequently Asked Questions How have HUMA shares performed this year? Humacyte's stock was trading at $2.84 at the beginning of 2024. Since then, HUMA stock has increased by 101.4% and is now trading at $5.72. View the best growth stocks for 2024 here. How were Humacyte's earnings last quarter? Humacyte, Inc. (NASDAQ:HUMA) announced its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.04. Who are Humacyte's major shareholders? Top institutional investors of Humacyte include Private Advisor Group LLC (0.31%), Wealth Effects LLC (0.05%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Brady W Dougan, Laura E Niklason, Gordon M Binder, Kathleen Sebelius, William John Scheessele, Michael T Constantino, Heather Ledbetter Prichard and Dale A Sander. View institutional ownership trends. How do I buy shares of Humacyte? Shares of HUMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Humacyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Humacyte investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Intel (INTC), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG). Company Calendar Last Earnings8/13/2024Today10/23/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HUMA CUSIPN/A CIK1818382 Webwww.constellationalpha.com Phone919-313-9633FaxN/AEmployees150Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$15.00 Low Stock Price Target$6.00 Potential Upside/Downside+74.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-110,780,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-942.81% Return on Assets-79.04% Debt Debt-to-Equity Ratio0.61 Current Ratio5.41 Quick Ratio5.41 Sales & Book Value Annual Sales$1.57 million Price / Sales433.86 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book44.00Miscellaneous Outstanding Shares119,084,000Free Float105,984,000Market Cap$681.16 million OptionableOptionable Beta1.45 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:HUMA) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.